following a full submission:
rilpivirine, emtricitabine, tenofovir disoproxil fumarate tablet (Eviplera®) is accepted for use within NHS Scotland.
Indication under review: treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.
Rilpivirine, emtricitabine, tenofovir (Eviplera®) maintained virological suppression in patients switched from other antiretroviral regimens. There is no evidence of efficacy in patients switching from other antiretroviral regimens due to virological failure.
SMC issued advice in February 2012 regarding the use of Eviplera® in antiretroviral treatment-naive adult patients. The current advice extends use to antiretroviral treatment-experienced patients.
Download detailed advice147KB (PDF)
Medicine details
- Medicine name:
- rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg tablet (Eviplera®)
- SMC ID:
- 951/14
- Indication:
- Treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 April 2014